Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study.
Prete AA, Manca P, Messina M, Formica V, Frassineti GL, Zampino MG, Corsi DC, Orciuolo C, Prisciandaro M, Bergamo F, Angerilli V, Scartozzi M, Casagrande M, Masi G, Ronzoni M, Morano F, Vettore V, Salmaso R, Rasola C, Maddalena G, Del Bianco P, Milione M, Cremolini C, Fassan M, Pietrantonio F, Lonardi S. Prete AA, et al. Among authors: milione m. Eur J Cancer. 2023 Mar;182:87-97. doi: 10.1016/j.ejca.2022.12.025. Epub 2023 Jan 9. Eur J Cancer. 2023. PMID: 36753836 Free article. Clinical Trial.
Role of BAX for outcome prediction in gastrointestinal malignancies.
Pietrantonio F, Biondani P, Ciurlia E, Fanetti G, Tessari A, Bertarelli G, Bossi I, Musella V, Melotti F, Di Bartolomeo M, Valvo F, Pellegrinelli A, Milione M, Perrone F, de Braud F. Pietrantonio F, et al. Among authors: milione m. Med Oncol. 2013;30(3):610. doi: 10.1007/s12032-013-0610-z. Epub 2013 May 23. Med Oncol. 2013. PMID: 23700226 Review.
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.
Pietrantonio F, Maggi C, Di Bartolomeo M, Facciorusso MG, Perrone F, Testi A, Iacovelli R, Miceli R, Bossi I, Leone G, Milione M, Pelosi G, de Braud F. Pietrantonio F, et al. Among authors: milione m. PLoS One. 2014 Apr 1;9(4):e92147. doi: 10.1371/journal.pone.0092147. eCollection 2014. PLoS One. 2014. PMID: 24691006 Free PMC article.
TP53 mutations in advanced colorectal cancer: the dark side of the moon.
Pietrantonio F, Biondani P, Perrone F, Di Bartolomeo M, Pacifici M, Milione M, Melotti F, Maggi C, Montemurro G, Bossi I, Mariani L, de Braud F. Pietrantonio F, et al. Among authors: milione m. Oncology. 2014;86(5-6):289-94. doi: 10.1159/000360088. Epub 2014 Jun 7. Oncology. 2014. PMID: 24924261
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
Pietrantonio F, Mazzaferro V, Miceli R, Cotsoglou C, Melotti F, Fanetti G, Perrone F, Biondani P, Muscarà C, Di Bartolomeo M, Coppa J, Maggi C, Milione M, Tamborini E, de Braud F. Pietrantonio F, et al. Among authors: milione m. Med Oncol. 2015 Jul;32(7):182. doi: 10.1007/s12032-015-0638-3. Epub 2015 May 24. Med Oncol. 2015. PMID: 26003673
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, Pietrantonio F. Cremolini C, et al. Among authors: milione m. Ann Oncol. 2015 Oct;26(10):2092-7. doi: 10.1093/annonc/mdv290. Epub 2015 Jul 7. Ann Oncol. 2015. PMID: 26153495 Free article.
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
Pietrantonio F, de Braud F, Milione M, Maggi C, Iacovelli R, Dotti KF, Perrone F, Tamborini E, Caporale M, Berenato R, Leone G, Pellegrinelli A, Bossi I, Festinese F, Federici S, Di Bartolomeo M. Pietrantonio F, et al. Among authors: milione m. Target Oncol. 2016 Jun;11(3):337-43. doi: 10.1007/s11523-015-0397-2. Target Oncol. 2016. PMID: 26538496
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
Pietrantonio F, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, Tamborini E, Baratti D, Kusamura S, Mariani L, Niger M, Mennitto A, Gloghini A, Bossi I, Settanni G, Busico A, Bagnoli PF, Di Bartolomeo M, Deraco M, de Braud F. Pietrantonio F, et al. Among authors: milione m. J Transl Med. 2016 May 6;14(1):125. doi: 10.1186/s12967-016-0877-x. J Transl Med. 2016. PMID: 27154293 Free PMC article. Clinical Trial.
Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.
Baratti D, Kusamura S, Milione M, Pietrantonio F, Caporale M, Guaglio M, Deraco M. Baratti D, et al. Among authors: milione m. Ann Surg Oncol. 2016 Dec;23(13):4222-4230. doi: 10.1245/s10434-016-5350-9. Epub 2016 Jun 28. Ann Surg Oncol. 2016. PMID: 27352203
215 results